Warsaw

• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma
• Dose-finding study of LAD603 in adults with alopecia areata Recruiting
  2025-523342-27-00 4 2026-04-10 Alopecia areata
• A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting
  2025-522782-30-00 3 2026-04-07 CCI
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting
  2025-520902-37-00 4 2026-04-01 Non-small cell lung cancer stage IV
• A Study in Pediatric Participants with Congenital Adrenal Hyperplasia Recruiting
  2024-519578-38-00 10 2026-03-30 Classic congenital adrenal hyperplasia
• A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have … Recruiting
  2025-521730-28-00 4 2026-03-30 Colorectal Cancer with Cancer Cachexia
• A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting
  2025-521142-22-00 5 2026-03-27 Hereditary Angioedema
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth … Recruiting
  2025-522492-28-00 4 2026-03-13 AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• Essentiale® liquid once-daily Phase III study Recruiting
  2025-521678-32-00 5 2026-03-03 MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) / MAS
• A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting
  2025-521939-36-00 4 2026-03-03 Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
• A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol … Recruiting
  2025-521845-26-00 5 2026-03-02 BP-I mania or mania with mixed features
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting
  2024-515332-80-00 5 2026-02-23 Bacterial vaginosis
• First-in-Human Study of RO7812653 Recruiting
  2025-522101-37-00 1 2026-02-17 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairmen
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety … Recruiting
  2024-520098-12-00 4 2026-02-16 Cutaneous Lupus Erythematosus
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• Zasocitinib in Nonsegmental Vitiligo Recruiting
  2025-522309-40-00 4 2026-02-11 Non-segmental vitiligo
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1

Showing 145–168 of 1,708 trials